Patents by Inventor Erinn Bruno Rankin

Erinn Bruno Rankin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified AXL Peptides and Their Use in Inhibition of AXL Signaling in Anti-Metastatic Therapy
    Publication number: 20220220458
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Application
    Filed: September 2, 2021
    Publication date: July 14, 2022
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Cynthia Fuh, Yu Miao, Susan Hershenson
  • Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
    Patent number: 11136563
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: October 5, 2021
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, ARAVIVE BIOLOGICS, INC.
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Cynthia Fuh, Yu Miao, Susan Hershenson
  • INHIBITION OF AXL/GAS6 SIGNALING IN THE TREATMENT OF LIVER FIBROSIS
    Publication number: 20180094034
    Abstract: Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 5, 2018
    Inventors: Patrick O'Connor, Raymond Tabibiazar, Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • MODIFIED AXL PEPTIDES AND THEIR USE IN INHIBITION OF AXL SIGNALING IN ANTI-METASTATIC THERAPY
    Publication number: 20180030422
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 1, 2018
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Cynthia Fuh, Yu Miao, Susan Hershenson
  • Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
    Patent number: 9879061
    Abstract: Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: January 30, 2018
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Aravive Biologics, Inc.
    Inventors: Patrick O'Connor, Raymond Tabibiazar, Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
    Patent number: 9822347
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: November 21, 2017
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Aravive Biologics, Inc.
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao, Susan Hershenson
  • Inhibition of AXL Signaling in Anti-Metastatic Therapy
    Publication number: 20160108378
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
    Type: Application
    Filed: May 14, 2015
    Publication date: April 21, 2016
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Inhibition of AXL signaling in anti-metastatic therapy
    Patent number: 9266947
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: February 23, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Modified AXL Peptides and Their Use in Inhibition of AXL Signaling in Anti-Metastatic Therapy
    Publication number: 20150315553
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Application
    Filed: December 12, 2013
    Publication date: November 5, 2015
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao, Susan Hershenson
  • Inhibition of AXL Signaling in Primary Tumor Therapy
    Publication number: 20150315552
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Application
    Filed: December 12, 2013
    Publication date: November 5, 2015
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Inhibition of AXL signaling in anti-metastatic therapy
    Patent number: 9074192
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: July 7, 2015
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Inhibition of AXL Signaling in Anti-Metastatic Therapy
    Publication number: 20140065143
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
    Type: Application
    Filed: July 24, 2013
    Publication date: March 6, 2014
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Inhibition of AXL signaling in anti-metastatic therapy
    Patent number: 8618254
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: December 31, 2013
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Inhibition of AXL Signaling in Anti-Metastatic Therapy
    Publication number: 20130108644
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
    Type: Application
    Filed: August 27, 2012
    Publication date: May 2, 2013
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Inhibition of AXL Signaling in Anti-Metastatic Therapy
    Publication number: 20130017205
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
    Type: Application
    Filed: July 20, 2012
    Publication date: January 17, 2013
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao